Biogen taps Danish biotech firm for collaboration on novel Lupus treatment
Biotech firm ISD Immunotech has entered into collaboration with US Biogen to develop the Danish firm's drug candidate for the autoimmune disease Lupus. If everything goes well, the drug can go on a market in 2028.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
ISD Immunotech has joined forced with one of the biggest players in the pharmaceutical world, and they share an ambition to develop the Danish firm's drug candidate for the treatment of a variant of the autoimmune disease lupus.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
